Job title: Director, Precision Medicine Quality Initiatives & Partnerships
With over 23 years of experience in the lab industry, working for many large commercial labs in Management of Sales related roles, Julie joined AstraZeneca Oncology in July 2019 as the new Director of Precision Medicine and Quality Initiatives and Partnerships expanding AstraZeneca’s partnerships with labs and professional organizations related and working with large health systems and centers to expand and educate around precision medicine. Previously of Pfizer Oncology the five years prior providing subject matter expertise to their growing portfolio of therapies with companion diagnostic activities. With expansive background in pathology, technologies, platforms, reimbursement and regulatory matters, Julie has also become one of the primary experts in data aggregation, purchase, and evaluation in biomarkers. Julie also serves on the Board of Directors for the California Clinical Lab Association as their previous president and now as the Secretary of the board. She is involved in many organizations such as Precision Medicine Coalition, and patient advocacy groups.
11.00 | 8.00 Commercialization Strategies for CDx in Precision Medicine in the US: Pitfalls & Considerations 11:00 am
day: Day 3